Human CD112/Nectin-2/PVRL2 HEK293T Stable Cell Line

Introduction

The Human CD112/Nectin-2/PVRL2 HEK293T Stable Cell Line is a valuable tool for studying the structure, activity, and potential therapeutic applications of CD112, also known as Nectin-2 or PVRL2. This stable cell line is derived from human embryonic kidney cells (HEK293T) and has been genetically modified to stably express CD112. In this article, we will explore the characteristics and potential uses of this cell line in scientific research.

Structure of CD112

CD112 is a transmembrane protein that belongs to the immunoglobulin superfamily. It is composed of an extracellular region, a transmembrane domain, and a cytoplasmic tail. The extracellular region of CD112 contains three immunoglobulin-like domains, which are involved in protein-protein interactions. The transmembrane domain anchors the protein to the cell membrane, while the cytoplasmic tail is responsible for intracellular signaling.

Activity of CD112

CD112 is primarily known for its role in immune cell communication. It is a ligand for the activating receptor CD226, also known as DNAM-1, which is expressed on natural killer (NK) cells, T cells, and other immune cells. Binding of CD112 to CD226 leads to the activation of these immune cells, resulting in the production of cytokines and cytotoxicity against target cells. This interaction is important for immune surveillance and defense against viral infections and cancer.
CD112 also interacts with other receptors, such as CD96 and TIGIT, which have inhibitory effects on immune cell activity. This complex network of interactions allows CD112 to modulate immune responses and maintain immune homeostasis.

Flow Cytometry Analysis of CD112 Expression

Flow cytometry is a powerful technique for analyzing the expression of cell surface proteins. The Human CD112/Nectin-2/PVRL2 HEK293T Stable Cell Line can be used as a positive control in flow cytometry experiments to detect CD112 expression. The cells can be stained with a fluorescently labeled antibody against CD112 and analyzed using a flow cytometer. This allows for the quantification of CD112 expression levels and the identification of CD112-positive cells in a heterogeneous cell population.

Therapeutic Target for Cancer and Viral Infections

Given its role in immune cell activation and communication, CD112 has emerged as a potential therapeutic target for cancer and viral infections. In cancer, CD112 expression is often dysregulated, leading to decreased immune cell recognition and increased tumor growth. Targeting CD112 with monoclonal antibodies or small molecule inhibitors has shown promising results in preclinical studies, and clinical trials are currently underway to evaluate the efficacy of these treatments in cancer patients.
In viral infections, CD112 is targeted by viruses such as herpes simplex virus type 1 (HSV-1) and cytomegalovirus (CMV) to evade immune detection. Inhibiting CD112-virus interactions could potentially enhance immune responses against these viruses and improve treatment outcomes. The Human CD112/Nectin-2/PVRL2 HEK293T Stable Cell Line can be used to study these interactions and develop novel antiviral therapies.

Conclusion

The Human CD112/Nectin-2/PVRL2 HEK293T Stable Cell Line is a valuable tool for studying the structure, activity, and potential therapeutic applications of CD112. Its stable expression of CD112 allows for reliable and consistent results in various experiments, including flow cytometry analysis. This cell line has the potential to advance our understanding of CD112 and its role in immune cell communication, as well as its potential as a therapeutic target for cancer and viral infections.